ARGX250516C410000
- 179.50
- 0.000.00%
argenx SE Newsroom
European Equities Traded in the US as American Depositary Receipts Drop Sharply in Wednesday Trading
J&J Wins FDA Approval for Myasthenia Gravis Therapy
P/E Ratio Insights for Argenx
Argenx Announces Positive CHMP Opinion for VYVGART (Efgartigimod Alfa) Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Wells Fargo Maintains Argenx SE(ARGX.US) With Buy Rating, Maintains Target Price $741
Argenx Se's Revenue Growth Potential Boosted by Vyvgart Hytrulo's Market Impact and Increased Treatment Cycles
Analysts Offer Insights on Healthcare Companies: Milestone Scientific (MLSS), Neurocrine (NBIX) and Argenx Se (ARGX)
What's Driving the Market Sentiment Around Argenx?
Argenx Price Target Lowered to EUR 680 From EUR 736 at BofA
Here's How Much You Would Have Made Owning Argenx Stock In The Last 5 Years
Citi Maintains Argenx SE(ARGX.US) With Buy Rating, Raises Target Price to $796
BofA Securities Maintains Argenx SE(ARGX.US) With Buy Rating, Maintains Target Price $774
TD Cowen Maintains Argenx SE(ARGX.US) With Buy Rating, Maintains Target Price $761
Argenx Is Maintained at Buy by Citigroup
Argenx Se (ARGX) Gets a Buy From TD Cowen
Bank of America Securities Sticks to Their Buy Rating for Argenx Se (ARGX)
Express News | Argenx SE : Citigroup Raises Target Price to $796 From $681
UBS Maintains Argenx SE(ARGX.US) With Hold Rating, Maintains Target Price $620
Argenx Se (ARGX) Gets a Hold From UBS
Wedbush Reiterates Outperform on Argenx, Maintains $715 Price Target